PRESTRELSKI STEVEN 4
4 · Xeris Biopharma Holdings, Inc. · Filed Feb 24, 2022
Insider Transaction Report
Form 4
PRESTRELSKI STEVEN
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-02-22$0.69/sh+11,228$7,747→ 581,008 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-02-22−11,228→ 0 totalExercise: $0.69From: 2022-02-22Exp: 2022-02-23→ Common Stock (11,228 underlying) - Sale
Common Stock
2022-02-22$2.42/sh−11,228$27,158→ 569,780 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]$2.4188 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.36 to $2.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These options are fully vested as of the date hereof.